Cellectis Provides Full Report for Second Quarter 2023 Financial Results
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS-…
Enterprise Resource Planning
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with…
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at…
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at…
Macquarie Capital Names Advisory Veteran Joseph Gatto as Senior Advisor – Global Consumer and Retail
Joseph Gatto will work with Macquarie Capital’s global consumer and retail team to advise clients…
ECI Software Solutions Announces Scalable Deacom Offering to Help SMBs Digitally Transform Their Businesses
Deacom Essentials offers batch and process manufacturers a cost-effective, tailored ERP FORT WORTH, Texas–(BUSINESS WIRE)–ECI…
Groundbreaking new £100m LifeArc programme aims to improve the lives of people living with a rare disease
MEDIA RELEASE Groundbreaking new £100m LifeArc programme aims to improve the lives of people living…
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
Topline data expected in July 2023 BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) —…
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
Topline data expected in July 2023 BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) —…
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics’ Founder & CEO, Scott…
Jonathan Milner issues Open Letter to shareholders of Abcam plc
Jonathan Milner issues Open Letter to shareholders of Abcam plc Responds to Company’s assertions in…
insightsoftware Extends Spreadsheet Server Reporting Capabilities with Infor FSM Integration
With no-code access to real-time data feeds, insightsoftware simplifies, accelerates, and strengthens reporting options for…
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD SOLANA BEACH,…
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD SOLANA BEACH,…
REPAY Integrates Accounts Payable Functionality into Microsoft Dynamics 365 Business Central
Integration designed to automate accounts payable, boost operational efficiencies and help businesses optimize digital B2B…
TESSCO Reports Fourth-Quarter Fiscal 2023 Financial Results
HUNT VALLEY, Md.–(BUSINESS WIRE)–TESSCO TECHNOLOGIES INCORPORATED (NASDAQ: TESS) today reported financial results for its fiscal…
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression…
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression…
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc)…
Mendus announces two upcoming presentations at the EHA2023 Hybrid Congress
MENDUS TO PRESENT UPDATES ON IMMUNOMONITORING DATA FROM ADVANCE II TRIAL AND PROGRESS ON THE…